Immunovant, Inc. (IMVT)
| Market Cap | 2.75B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -413.84M |
| Shares Out | 170.92M |
| EPS (ttm) | -2.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,764,732 |
| Open | 16.41 |
| Previous Close | 16.39 |
| Day's Range | 15.81 - 16.44 |
| 52-Week Range | 12.72 - 34.47 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 40.14 (+149.32%) |
| Earnings Date | Aug 5, 2025 |
About IMVT
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. wa... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for IMVT stock is "Buy." The 12-month stock price forecast is $40.14, which is an increase of 149.32% from the latest price.
News
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD) and...
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoc...
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their f...
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study
Immunovant aims to initiate a pivotal registration study for IMVT-1402 targeting Graves' Disease by the end of 2024, with 4–5 trials in other IgG-mediated autoimmune disorders by March 2025. IMVT-1402...
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial
Presents Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, and FcRn Inhibitor Market Size from 2020 to 2034 Presents Current Treatment Practices, Emerging Drugs, Marke...
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Top 2 Health Care Stocks That May Collapse This Quarter
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Immunovant Provides Update on Graves' Disease Development Program
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...
Immunovant to Host Graves' Disease Program Update on September 9, 2024
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging
In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 20...
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported c...
Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advanci...
Immunovant Awarded U.S. Patent for IMVT-1402
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...
Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas
Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech com...
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena
Immunovant continues to show promising developments in anti-FcRn platform's clinical trials and has a strong financial position. Key upcoming catalysts, including Phase 1 data and Phase 2 results, cou...